ArticleArchives of Iranian medicine2025
Burden of Tracheal, Bronchus, and Lung Cancer Attributable to High Fasting Plasma Glucose.
Article in Archives of Iranian medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Global burden of cancers attributable to high fasting plasma glucose from 1990 to 2021 and projections until 2031.Diabetology & metabolic syndrome · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aimed to evaluate the situation and change trends in the tracheal, bronchus, and lung (TBL) cancer burden attributable to high fasting plasma glucose (HFPG) stratified by gender, age, region, country, and sociodemographic index (SDI).
methodsWe evaluated the age-standardized death rate (ASDR) and disability-adjusted life years (DALYs) rate of TBL cancer attributable to HFPG and their corresponding estimated annual percentage change (EAPC) trends in 204 countries and 21 regions.
resultsGlobally from 1990 to 2019, the ASDR (EAPC=0.98; 95% confidence interval [CI]: 0.82-1.15) and age-standardized DALY rate (EAPC=0.68; 95% CI: 0.55-0.82) of TBL cancer attributable to HFPG trended upward. Furthermore, the steepest increment in age-standardized death and DALY rates were noted in low-SDI regions (EAPC=1.32; EAPC=1.35) and the North Africa/Middle East region (EAPC=2.66, ESPC=2.56) among all five SDI regions and 21 global geographic regions, respectively. Among the 204 countries, the highest growth rate in the ASDR was found in Georgia (EAPC=4.33, 95% CI: 3.66-5.00), and the highest growth rate in the age-standardized DALY rate occurred in Egypt (EAPC=4.34, 95% CI: 4.22-4.47). The highest ASDR and age-standardized DALY rate occurred in people over the age of 65 years, and in the 21 geographic regions, SDIs were negatively correlated with ASDRs and EAPCs in DALYs.
conclusionThe global burden of TBL cancer attributable to HFPG trended upward. The most significant increase in burden was observed in low-SDI regions and countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.